Aim: Research is ongoing to discover biomarkers that can be used to monitor disease progression and predict prognosis in peripheral artery disease (PAD). Ischemia-modified albumin (IMA) is known to predict the risk for PAD. The aim of this study was to investigate whether serum IMA levels were associated with PAD lesions and ankle-brachial index (ABI) values, and to determine the accuracy of IMA levels in predicting PAD prognosis. Material and Method: Seventy-three patients with PAD who applied

more »

... to our hospital between July and September 2018 were included in the study. The lesion levels of patients with an ankle-brachial index (ABI) value lower than or equal to 0.9 were determined by computed tomography angiography (CTA). Patients were grouped according to their lesion levels and Fontaine classification. Serum IMA concentrations were measured and compared with regard to lesion levels and ABI values. Results: Sixty-five of the patients (89%) were male. The mean age of the patients was 62.2±8.8 (43-77) years. The mean serum IMA level was 25.9±26.7 (10-218) ng/ml. Serum IMA levels were found to be lower in patients with bilateral iliac artery lesions (p=0.040). There was no statistically significant relationship between other parameters and serum IMA levels (p >0.05 for all). Conclusion: There is a need for biomarkers that can predict lesion level and prognosis in patients with PAD. Although no statistically significant relationship was found between lesion level and serum IMA concentrations in this study, further studies involving a higher number of patients may provide more informative data on this subject.